• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: AD

Targeting amyloid in AD – optimism amid controversy

January 15, 2020  

Pre-AAN Survey

March 27, 2019  

Two trials terminated in Alzheimer’s disease

January 31, 2019  

Third failed trial for solanezumab in AD

February 22, 2018  

IVIG: limited benefit in Alzheimer’s disease

August 2, 2017  

AAN 2017 DAILY REPORT

April 27, 2017  

Sun avoidance – more harm than good?

December 16, 2016  

Gum disease linked to cognitive decline in AD

December 7, 2016  

Iatrogenic Alzheimer’s – is AD transmissible?

November 9, 2016  

Novel CSF biomarkers being investigated in AD

August 10, 2016  
1
2
3
Next

Browse by Topic

MS (332)
AD (81)
PD (77)
COVID-19 (58)
PREVIOUS CONGRESSES (37)
DEPRESSION (36)
MIGRAINE (26)
SCHIZOPHRENIA (25)
STROKE (22)
EPILEPSY (21)
ECTRIMS 2015 (13)
Library (13)
AAN 2015 (11)
ECTRIMS 2019 (10)
ECTRIMS 2021 (10)
ECTRIMS 2014 (10)
DEMENTIA (10)
ECTRIMS 2018 (9)
MS SEQUENCING (9)
ECTRIMS 2013 (9)
AAN 2014 (9)
AAN 2013 (9)
CLINICAL CASES IN MS (8)
PSYCHIATRY (8)
AAN 2019 (7)
ACTRIMS-ECTRIMS 2020 (7)
ECTRIMS 2017 (6)
CHARCOT 2013 (6)
AAN 2021 (6)
ECTRIMS 2022 (6)
ECTRIMS 2016 (5)
CCSVI (5)
BIPOLAR (5)
ANXIETY (5)
AAN 2022 (5)
NeuroSound (4)
BPD (4)
EAN 2015 (4)
AAN 2020 (3)
PAIN (3)
EAN 2022 (3)
AAN 2017 (3)
ENS 2013 (3)
SPECIAL REPORT (2)
EAN 2020 (2)
NEW DRUGS (2)
SLEEP (2)
APA 2014 (2)
AAN 2018 (2)
hATTR (1)
LUMBAR PUNCTURE (1)
LGS (1)
GUIDELINES (1)
ACTRIMS 2022 (1)
SEIZURE (1)
ALS (1)
EAN 2021 (1)
TSC (1)
APA 2016 (1)
INSOMNIA (1)
AAN 2016 (1)
Dravet syndrome (1)
CIDP (1)
CONCUSSION (1)
ADDICTION (1)
WEST NILE (1)
EAN 2019 (1)
EAN 2016 (0)
ECTRIMS 2020 (0)
View all Topics

Popular Posts

  • CLINICAL CASES IN MS – AN OLDER PATIENT WITH STABLE DISEASE posted on January 10, 2023
  • The end of MS phenotypes? posted on January 26, 2023
  • MS Awards 2022 – Oddities and Observations posted on December 9, 2022
Copyright 2023 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions